Joint CTI-eGDR phenotypes and incident cardiovascular disease in CKM stages 0-3: A retrospective landmark analysis.
Abstract
Background
The joint cardiometabolic phenotypes of inflammatory-metabolic burden and insulin sensitivity based on repeated measurements their associations with the risk of cardiovascular disease (CVD) among individuals with cardiovascular-kidney-metabolic (CKM) syndrome remain unclear. We aimed to identify joint phenotypes in relation to C-reactive protein-triglyceride-glucose index (CTI) and estimated glucose disposal rate (eGDR) based on repeated measurements and evaluate their associations with incident CVD.
Methods
This retrospective landmark cohort analysis used prospectively collected CHARLS data from 4883 participants aged ≥45 years with CKM stages 0-3. CTI, eGDR, cumulative CTI (CuCTI), and cumulative eGDR were derived from measurements in 2011 and 2015. K-means clustering of repeated CTI and eGDR measurements was used to identify joint cardiometabolic phenotypes, and Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Dose-response, subgroup, and sensitivity analyses were performed.
Results
During a median post-landmark follow-up of 5.0 years, 1195 incident CVD events were identified. Three phenotypes were identified: low CTI-high eGDR (n = 2344), high CTI-intermediate eGDR (n = 1351), and intermediate CTI-low eGDR (n = 1188). The K = 3 solution showed high bootstrap reproducibility (median adjusted Rand index, 0.978), although cluster separation was modest. Compared with the first phenotype, the latter two were associated with higher CVD risk after multivariable adjustment (HR 1.25, 95% CI 1.08-1.46; and HR 2.12, 95% CI 1.86-2.42). Both CuCTI and cumulative low-eGDR burden were associated with CVD risk. Findings were generally robust across subgroup and sensitivity analyses.
Conclusions
Joint CTI-eGDR phenotypes based on repeated measurements were associated with incident CVD, with the intermediate CTI-low eGDR phenotype representing a higher-risk composite cardiometabolic profile.